Full Text of SB2341 100th General Assembly
SB2341eng 100TH GENERAL ASSEMBLY |
| | SB2341 Engrossed | | LRB100 17957 MRW 33141 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois, | 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Sections 102 and 204 as follows: | 6 | | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | 7 | | Sec. 102. Definitions. As used in this Act, unless the | 8 | | context
otherwise requires:
| 9 | | (a) "Addict" means any person who habitually uses any drug, | 10 | | chemical,
substance or dangerous drug other than alcohol so as | 11 | | to endanger the public
morals, health, safety or welfare or who | 12 | | is so far addicted to the use of a
dangerous drug or controlled | 13 | | substance other than alcohol as to have lost
the power of self | 14 | | control with reference to his or her addiction.
| 15 | | (b) "Administer" means the direct application of a | 16 | | controlled
substance, whether by injection, inhalation, | 17 | | ingestion, or any other
means, to the body of a patient, | 18 | | research subject, or animal (as
defined by the Humane | 19 | | Euthanasia in Animal Shelters Act) by:
| 20 | | (1) a practitioner (or, in his or her presence, by his | 21 | | or her authorized agent),
| 22 | | (2) the patient or research subject pursuant to an | 23 | | order, or
|
| | | SB2341 Engrossed | - 2 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (3) a euthanasia technician as defined by the Humane | 2 | | Euthanasia in
Animal Shelters Act.
| 3 | | (c) "Agent" means an authorized person who acts on behalf | 4 | | of or at
the direction of a manufacturer, distributor, | 5 | | dispenser, prescriber, or practitioner. It does not
include a | 6 | | common or contract carrier, public warehouseman or employee of
| 7 | | the carrier or warehouseman.
| 8 | | (c-1) "Anabolic Steroids" means any drug or hormonal | 9 | | substance,
chemically and pharmacologically related to | 10 | | testosterone (other than
estrogens, progestins, | 11 | | corticosteroids, and dehydroepiandrosterone),
and includes:
| 12 | | (i) 3[beta],17-dihydroxy-5a-androstane, | 13 | | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, | 14 | | (iii) 5[alpha]-androstan-3,17-dione, | 15 | | (iv) 1-androstenediol (3[beta], | 16 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | 17 | | (v) 1-androstenediol (3[alpha], | 18 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | 19 | | (vi) 4-androstenediol | 20 | | (3[beta],17[beta]-dihydroxy-androst-4-ene), | 21 | | (vii) 5-androstenediol | 22 | | (3[beta],17[beta]-dihydroxy-androst-5-ene), | 23 | | (viii) 1-androstenedione | 24 | | ([5alpha]-androst-1-en-3,17-dione), | 25 | | (ix) 4-androstenedione | 26 | | (androst-4-en-3,17-dione), |
| | | SB2341 Engrossed | - 3 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (x) 5-androstenedione | 2 | | (androst-5-en-3,17-dione), | 3 | | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | 4 | | hydroxyandrost-4-en-3-one), | 5 | | (xii) boldenone (17[beta]-hydroxyandrost- | 6 | | 1,4,-diene-3-one), | 7 | | (xiii) boldione (androsta-1,4- | 8 | | diene-3,17-dione), | 9 | | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | 10 | | [beta]-hydroxyandrost-4-en-3-one), | 11 | | (xv) clostebol (4-chloro-17[beta]- | 12 | | hydroxyandrost-4-en-3-one), | 13 | | (xvi) dehydrochloromethyltestosterone (4-chloro- | 14 | | 17[beta]-hydroxy-17[alpha]-methyl- | 15 | | androst-1,4-dien-3-one), | 16 | | (xvii) desoxymethyltestosterone | 17 | | (17[alpha]-methyl-5[alpha] | 18 | | -androst-2-en-17[beta]-ol)(a.k.a., madol), | 19 | | (xviii) [delta]1-dihydrotestosterone (a.k.a. | 20 | | '1-testosterone') (17[beta]-hydroxy- | 21 | | 5[alpha]-androst-1-en-3-one), | 22 | | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | 23 | | androstan-3-one), | 24 | | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | 25 | | 5[alpha]-androstan-3-one), | 26 | | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- |
| | | SB2341 Engrossed | - 4 - | LRB100 17957 MRW 33141 b |
|
| 1 | | hydroxyestr-4-ene), | 2 | | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | 3 | | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | 4 | | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | 5 | | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | 6 | | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | 7 | | hydroxyandrostano[2,3-c]-furazan), | 8 | | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one , ) | 9 | | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | 10 | | androst-4-en-3-one), | 11 | | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | 12 | | dihydroxy-estr-4-en-3-one), | 13 | | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- | 14 | | hydroxy-5-androstan-3-one), | 15 | | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | 16 | | [5a]-androstan-3-one), | 17 | | (xxx) methandienone (17[alpha]-methyl-17[beta]- | 18 | | hydroxyandrost-1,4-dien-3-one), | 19 | | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | 20 | | dihydroxyandrost-5-ene), | 21 | | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | 22 | | 5[alpha]-androst-1-en-3-one), | 23 | | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | 24 | | dihydroxy-5a-androstane ) , | 25 | | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy | 26 | | -5a-androstane ) , |
| | | SB2341 Engrossed | - 5 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | 2 | | dihydroxyandrost-4-ene), | 3 | | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | 4 | | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | 5 | | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | 6 | | hydroxyestra-4,9(10)-dien-3-one), | 7 | | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | 8 | | hydroxyestra-4,9-11-trien-3-one), | 9 | | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | 10 | | hydroxyandrost-4-en-3-one), | 11 | | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | 12 | | hydroxyestr-4-en-3-one), | 13 | | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | 14 | | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | 15 | | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | 16 | | 1-testosterone'), | 17 | | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | 18 | | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | 19 | | dihydroxyestr-4-ene), | 20 | | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- | 21 | | dihydroxyestr-4-ene), | 22 | | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | 23 | | dihydroxyestr-5-ene), | 24 | | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | 25 | | dihydroxyestr-5-ene), | 26 | | (xlvii) 19-nor-4,9(10)-androstadienedione |
| | | SB2341 Engrossed | - 6 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (estra-4,9(10)-diene-3,17-dione), | 2 | | (xlviii) 19-nor-4-androstenedione (estr-4- | 3 | | en-3,17-dione), | 4 | | (xlix) 19-nor-5-androstenedione (estr-5- | 5 | | en-3,17-dione), | 6 | | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | 7 | | hydroxygon-4-en-3-one), | 8 | | (li) norclostebol (4-chloro-17[beta]- | 9 | | hydroxyestr-4-en-3-one), | 10 | | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | 11 | | hydroxyestr-4-en-3-one), | 12 | | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | 13 | | hydroxyestr-4-en-3-one), | 14 | | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | 15 | | 2-oxa-5[alpha]-androstan-3-one), | 16 | | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | 17 | | dihydroxyandrost-4-en-3-one), | 18 | | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | 19 | | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | 20 | | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- | 21 | | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | 22 | | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | 23 | | (5[alpha]-androst-1-en-3-one), | 24 | | (lix) testolactone (13-hydroxy-3-oxo-13,17- | 25 | | secoandrosta-1,4-dien-17-oic | 26 | | acid lactone), |
| | | SB2341 Engrossed | - 7 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (lx) testosterone (17[beta]-hydroxyandrost- | 2 | | 4-en-3-one), | 3 | | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | 4 | | diethyl-17[beta]-hydroxygon- | 5 | | 4,9,11-trien-3-one), | 6 | | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | 7 | | 11-trien-3-one).
| 8 | | Any person who is otherwise lawfully in possession of an | 9 | | anabolic
steroid, or who otherwise lawfully manufactures, | 10 | | distributes, dispenses,
delivers, or possesses with intent to | 11 | | deliver an anabolic steroid, which
anabolic steroid is | 12 | | expressly intended for and lawfully allowed to be
administered | 13 | | through implants to livestock or other nonhuman species, and
| 14 | | which is approved by the Secretary of Health and Human Services | 15 | | for such
administration, and which the person intends to | 16 | | administer or have
administered through such implants, shall | 17 | | not be considered to be in
unauthorized possession or to | 18 | | unlawfully manufacture, distribute, dispense,
deliver, or | 19 | | possess with intent to deliver such anabolic steroid for
| 20 | | purposes of this Act.
| 21 | | (d) "Administration" means the Drug Enforcement | 22 | | Administration,
United States Department of Justice, or its | 23 | | successor agency.
| 24 | | (d-5) "Clinical Director, Prescription Monitoring Program" | 25 | | means a Department of Human Services administrative employee | 26 | | licensed to either prescribe or dispense controlled substances |
| | | SB2341 Engrossed | - 8 - | LRB100 17957 MRW 33141 b |
|
| 1 | | who shall run the clinical aspects of the Department of Human | 2 | | Services Prescription Monitoring Program and its Prescription | 3 | | Information Library. | 4 | | (d-10) "Compounding" means the preparation and mixing of | 5 | | components, excluding flavorings, (1) as the result of a | 6 | | prescriber's prescription drug order or initiative based on the | 7 | | prescriber-patient-pharmacist relationship in the course of | 8 | | professional practice or (2) for the purpose of, or incident | 9 | | to, research, teaching, or chemical analysis and not for sale | 10 | | or dispensing. "Compounding" includes the preparation of drugs | 11 | | or devices in anticipation of receiving prescription drug | 12 | | orders based on routine, regularly observed dispensing | 13 | | patterns. Commercially available products may be compounded | 14 | | for dispensing to individual patients only if both of the | 15 | | following conditions are met: (i) the commercial product is not | 16 | | reasonably available from normal distribution channels in a | 17 | | timely manner to meet the patient's needs and (ii) the | 18 | | prescribing practitioner has requested that the drug be | 19 | | compounded. | 20 | | (e) "Control" means to add a drug or other substance, or | 21 | | immediate
precursor, to a Schedule whether by
transfer from | 22 | | another Schedule or otherwise.
| 23 | | (f) "Controlled Substance" means (i) a drug, substance, | 24 | | immediate
precursor, or synthetic drug in the Schedules of | 25 | | Article II of this Act or (ii) a drug or other substance, or | 26 | | immediate precursor, designated as a controlled substance by |
| | | SB2341 Engrossed | - 9 - | LRB100 17957 MRW 33141 b |
|
| 1 | | the Department through administrative rule. The term does not | 2 | | include distilled spirits, wine, malt beverages, or tobacco, as | 3 | | those terms are
defined or used in the Liquor Control Act of | 4 | | 1934 and the Tobacco Products Tax
Act of 1995.
| 5 | | (f-5) "Controlled substance analog" means a substance: | 6 | | (1) the chemical structure of which is substantially | 7 | | similar to the chemical structure of a controlled substance | 8 | | in Schedule I or II; | 9 | | (2) which has a stimulant, depressant, or | 10 | | hallucinogenic effect on the central nervous system that is | 11 | | substantially similar to or greater than the stimulant, | 12 | | depressant, or hallucinogenic effect on the central | 13 | | nervous system of a controlled substance in Schedule I or | 14 | | II; or | 15 | | (3) with respect to a particular person, which such | 16 | | person represents or intends to have a stimulant, | 17 | | depressant, or hallucinogenic effect on the central | 18 | | nervous system that is substantially similar to or greater | 19 | | than the stimulant, depressant, or hallucinogenic effect | 20 | | on the central nervous system of a controlled substance in | 21 | | Schedule I or II. | 22 | | (g) "Counterfeit substance" means a controlled substance, | 23 | | which, or
the container or labeling of which, without | 24 | | authorization bears the
trademark, trade name, or other | 25 | | identifying mark, imprint, number or
device, or any likeness | 26 | | thereof, of a manufacturer, distributor, or
dispenser other |
| | | SB2341 Engrossed | - 10 - | LRB100 17957 MRW 33141 b |
|
| 1 | | than the person who in fact manufactured, distributed,
or | 2 | | dispensed the substance.
| 3 | | (h) "Deliver" or "delivery" means the actual, constructive | 4 | | or
attempted transfer of possession of a controlled substance, | 5 | | with or
without consideration, whether or not there is an | 6 | | agency relationship.
| 7 | | (i) "Department" means the Illinois Department of Human | 8 | | Services (as
successor to the Department of Alcoholism and | 9 | | Substance Abuse) or its successor agency.
| 10 | | (j) (Blank).
| 11 | | (k) "Department of Corrections" means the Department of | 12 | | Corrections
of the State of Illinois or its successor agency.
| 13 | | (l) "Department of Financial and Professional Regulation" | 14 | | means the Department
of Financial and Professional Regulation | 15 | | of the State of Illinois or its successor agency.
| 16 | | (m) "Depressant" means any drug that (i) causes an overall | 17 | | depression of central nervous system functions, (ii) causes | 18 | | impaired consciousness and awareness, and (iii) can be | 19 | | habit-forming or lead to a substance abuse problem, including | 20 | | but not limited to alcohol, cannabis and its active principles | 21 | | and their analogs, benzodiazepines and their analogs, | 22 | | barbiturates and their analogs, opioids (natural and | 23 | | synthetic) and their analogs, and chloral hydrate and similar | 24 | | sedative hypnotics.
| 25 | | (n) (Blank).
| 26 | | (o) "Director" means the Director of the Illinois State |
| | | SB2341 Engrossed | - 11 - | LRB100 17957 MRW 33141 b |
|
| 1 | | Police or his or her designated agents.
| 2 | | (p) "Dispense" means to deliver a controlled substance to | 3 | | an
ultimate user or research subject by or pursuant to the | 4 | | lawful order of
a prescriber, including the prescribing, | 5 | | administering, packaging,
labeling, or compounding necessary | 6 | | to prepare the substance for that
delivery.
| 7 | | (q) "Dispenser" means a practitioner who dispenses.
| 8 | | (r) "Distribute" means to deliver, other than by | 9 | | administering or
dispensing, a controlled substance.
| 10 | | (s) "Distributor" means a person who distributes.
| 11 | | (t) "Drug" means (1) substances recognized as drugs in the | 12 | | official
United States Pharmacopoeia, Official Homeopathic | 13 | | Pharmacopoeia of the
United States, or official National | 14 | | Formulary, or any supplement to any
of them; (2) substances | 15 | | intended for use in diagnosis, cure, mitigation,
treatment, or | 16 | | prevention of disease in man or animals; (3) substances
(other | 17 | | than food) intended to affect the structure of any function of
| 18 | | the body of man or animals and (4) substances intended for use | 19 | | as a
component of any article specified in clause (1), (2), or | 20 | | (3) of this
subsection. It does not include devices or their | 21 | | components, parts, or
accessories.
| 22 | | (t-3) "Electronic health record" or "EHR" means an | 23 | | electronic record of health-related information on an | 24 | | individual that is created, gathered, managed, and consulted by | 25 | | authorized health care clinicians and staff. | 26 | | (t-4) "Emergency medical services personnel" has the |
| | | SB2341 Engrossed | - 12 - | LRB100 17957 MRW 33141 b |
|
| 1 | | meaning ascribed to it in the Emergency Medical Services (EMS) | 2 | | Systems Act. | 3 | | (t-5) "Euthanasia agency" means
an entity certified by the | 4 | | Department of Financial and Professional Regulation for the
| 5 | | purpose of animal euthanasia that holds an animal control | 6 | | facility license or
animal
shelter license under the Animal | 7 | | Welfare Act. A euthanasia agency is
authorized to purchase, | 8 | | store, possess, and utilize Schedule II nonnarcotic and
| 9 | | Schedule III nonnarcotic drugs for the sole purpose of animal | 10 | | euthanasia.
| 11 | | (t-10) "Euthanasia drugs" means Schedule II or Schedule III | 12 | | substances
(nonnarcotic controlled substances) that are used | 13 | | by a euthanasia agency for
the purpose of animal euthanasia.
| 14 | | (u) "Good faith" means the prescribing or dispensing of a | 15 | | controlled
substance by a practitioner in the regular course of | 16 | | professional
treatment to or for any person who is under his or | 17 | | her treatment for a
pathology or condition other than that | 18 | | individual's physical or
psychological dependence upon or | 19 | | addiction to a controlled substance,
except as provided herein: | 20 | | and application of the term to a pharmacist
shall mean the | 21 | | dispensing of a controlled substance pursuant to the
| 22 | | prescriber's order which in the professional judgment of the | 23 | | pharmacist
is lawful. The pharmacist shall be guided by | 24 | | accepted professional
standards including, but not limited to | 25 | | the following, in making the
judgment:
| 26 | | (1) lack of consistency of prescriber-patient |
| | | SB2341 Engrossed | - 13 - | LRB100 17957 MRW 33141 b |
|
| 1 | | relationship,
| 2 | | (2) frequency of prescriptions for same drug by one | 3 | | prescriber for
large numbers of patients,
| 4 | | (3) quantities beyond those normally prescribed,
| 5 | | (4) unusual dosages (recognizing that there may be | 6 | | clinical circumstances where more or less than the usual | 7 | | dose may be used legitimately),
| 8 | | (5) unusual geographic distances between patient, | 9 | | pharmacist and
prescriber,
| 10 | | (6) consistent prescribing of habit-forming drugs.
| 11 | | (u-0.5) "Hallucinogen" means a drug that causes markedly | 12 | | altered sensory perception leading to hallucinations of any | 13 | | type. | 14 | | (u-1) "Home infusion services" means services provided by a | 15 | | pharmacy in
compounding solutions for direct administration to | 16 | | a patient in a private
residence, long-term care facility, or | 17 | | hospice setting by means of parenteral,
intravenous, | 18 | | intramuscular, subcutaneous, or intraspinal infusion.
| 19 | | (u-5) "Illinois State Police" means the State
Police of the | 20 | | State of Illinois, or its successor agency. | 21 | | (v) "Immediate precursor" means a substance:
| 22 | | (1) which the Department has found to be and by rule | 23 | | designated as
being a principal compound used, or produced | 24 | | primarily for use, in the
manufacture of a controlled | 25 | | substance;
| 26 | | (2) which is an immediate chemical intermediary used or |
| | | SB2341 Engrossed | - 14 - | LRB100 17957 MRW 33141 b |
|
| 1 | | likely to
be used in the manufacture of such controlled | 2 | | substance; and
| 3 | | (3) the control of which is necessary to prevent, | 4 | | curtail or limit
the manufacture of such controlled | 5 | | substance.
| 6 | | (w) "Instructional activities" means the acts of teaching, | 7 | | educating
or instructing by practitioners using controlled | 8 | | substances within
educational facilities approved by the State | 9 | | Board of Education or
its successor agency.
| 10 | | (x) "Local authorities" means a duly organized State, | 11 | | County or
Municipal peace unit or police force.
| 12 | | (y) "Look-alike substance" means a substance, other than a | 13 | | controlled
substance which (1) by overall dosage unit | 14 | | appearance, including shape,
color, size, markings or lack | 15 | | thereof, taste, consistency, or any other
identifying physical | 16 | | characteristic of the substance, would lead a reasonable
person | 17 | | to believe that the substance is a controlled substance, or (2) | 18 | | is
expressly or impliedly represented to be a controlled | 19 | | substance or is
distributed under circumstances which would | 20 | | lead a reasonable person to
believe that the substance is a | 21 | | controlled substance. For the purpose of
determining whether | 22 | | the representations made or the circumstances of the
| 23 | | distribution would lead a reasonable person to believe the | 24 | | substance to be
a controlled substance under this clause (2) of | 25 | | subsection (y), the court or
other authority may consider the | 26 | | following factors in addition to any other
factor that may be |
| | | SB2341 Engrossed | - 15 - | LRB100 17957 MRW 33141 b |
|
| 1 | | relevant:
| 2 | | (a) statements made by the owner or person in control | 3 | | of the substance
concerning its nature, use or effect;
| 4 | | (b) statements made to the buyer or recipient that the | 5 | | substance may
be resold for profit;
| 6 | | (c) whether the substance is packaged in a manner | 7 | | normally used for the
illegal distribution of controlled | 8 | | substances;
| 9 | | (d) whether the distribution or attempted distribution | 10 | | included an
exchange of or demand for money or other | 11 | | property as consideration, and
whether the amount of the | 12 | | consideration was substantially greater than the
| 13 | | reasonable retail market value of the substance.
| 14 | | Clause (1) of this subsection (y) shall not apply to a | 15 | | noncontrolled
substance in its finished dosage form that was | 16 | | initially introduced into
commerce prior to the initial | 17 | | introduction into commerce of a controlled
substance in its | 18 | | finished dosage form which it may substantially resemble.
| 19 | | Nothing in this subsection (y) prohibits the dispensing or | 20 | | distributing
of noncontrolled substances by persons authorized | 21 | | to dispense and
distribute controlled substances under this | 22 | | Act, provided that such action
would be deemed to be carried | 23 | | out in good faith under subsection (u) if the
substances | 24 | | involved were controlled substances.
| 25 | | Nothing in this subsection (y) or in this Act prohibits the | 26 | | manufacture,
preparation, propagation, compounding, |
| | | SB2341 Engrossed | - 16 - | LRB100 17957 MRW 33141 b |
|
| 1 | | processing, packaging, advertising
or distribution of a drug or | 2 | | drugs by any person registered pursuant to
Section 510 of the | 3 | | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| 4 | | (y-1) "Mail-order pharmacy" means a pharmacy that is | 5 | | located in a state
of the United States that delivers, | 6 | | dispenses or
distributes, through the United States Postal | 7 | | Service or other common
carrier, to Illinois residents, any | 8 | | substance which requires a prescription.
| 9 | | (z) "Manufacture" means the production, preparation, | 10 | | propagation,
compounding, conversion or processing of a | 11 | | controlled substance other than methamphetamine, either
| 12 | | directly or indirectly, by extraction from substances of | 13 | | natural origin,
or independently by means of chemical | 14 | | synthesis, or by a combination of
extraction and chemical | 15 | | synthesis, and includes any packaging or
repackaging of the | 16 | | substance or labeling of its container, except that
this term | 17 | | does not include:
| 18 | | (1) by an ultimate user, the preparation or compounding | 19 | | of a
controlled substance for his or her own use; or
| 20 | | (2) by a practitioner, or his or her authorized agent | 21 | | under his or her
supervision, the preparation, | 22 | | compounding, packaging, or labeling of a
controlled | 23 | | substance:
| 24 | | (a) as an incident to his or her administering or | 25 | | dispensing of a
controlled substance in the course of | 26 | | his or her professional practice; or
|
| | | SB2341 Engrossed | - 17 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (b) as an incident to lawful research, teaching or | 2 | | chemical
analysis and not for sale.
| 3 | | (z-1) (Blank).
| 4 | | (z-5) "Medication shopping" means the conduct prohibited | 5 | | under subsection (a) of Section 314.5 of this Act. | 6 | | (z-10) "Mid-level practitioner" means (i) a physician | 7 | | assistant who has been delegated authority to prescribe through | 8 | | a written delegation of authority by a physician licensed to | 9 | | practice medicine in all of its branches, in accordance with | 10 | | Section 7.5 of the Physician Assistant Practice Act of 1987, | 11 | | (ii) an advanced practice registered nurse who has been | 12 | | delegated authority to prescribe through a written delegation | 13 | | of authority by a physician licensed to practice medicine in | 14 | | all of its branches or by a podiatric physician, in accordance | 15 | | with Section 65-40 of the Nurse Practice Act, (iii) an advanced | 16 | | practice registered nurse certified as a nurse practitioner, | 17 | | nurse midwife, or clinical nurse specialist who has been | 18 | | granted authority to prescribe by a hospital affiliate in | 19 | | accordance with Section 65-45 of the Nurse Practice Act, (iv) | 20 | | an animal euthanasia agency, or (v) a prescribing psychologist. | 21 | | (aa) "Narcotic drug" means any of the following, whether | 22 | | produced
directly or indirectly by extraction from substances | 23 | | of vegetable origin,
or independently by means of chemical | 24 | | synthesis, or by a combination of
extraction and chemical | 25 | | synthesis:
| 26 | | (1) opium, opiates, derivatives of opium and opiates, |
| | | SB2341 Engrossed | - 18 - | LRB100 17957 MRW 33141 b |
|
| 1 | | including their isomers, esters, ethers, salts, and salts | 2 | | of isomers, esters, and ethers, whenever the existence of | 3 | | such isomers, esters, ethers, and salts is possible within | 4 | | the specific chemical designation; however the term | 5 | | "narcotic drug" does not include the isoquinoline | 6 | | alkaloids of opium;
| 7 | | (2) (blank);
| 8 | | (3) opium poppy and poppy straw;
| 9 | | (4) coca leaves, except coca leaves and extracts of | 10 | | coca leaves from which substantially all of the cocaine and | 11 | | ecgonine, and their isomers, derivatives and salts, have | 12 | | been removed;
| 13 | | (5) cocaine, its salts, optical and geometric isomers, | 14 | | and salts of isomers; | 15 | | (6) ecgonine, its derivatives, their salts, isomers, | 16 | | and salts of isomers; | 17 | | (7) any compound, mixture, or preparation which | 18 | | contains any quantity of any of the substances referred to | 19 | | in subparagraphs (1) through (6). | 20 | | (bb) "Nurse" means a registered nurse licensed under the
| 21 | | Nurse Practice Act.
| 22 | | (cc) (Blank).
| 23 | | (dd) "Opiate" means any substance having an addiction | 24 | | forming or
addiction sustaining liability similar to morphine | 25 | | or being capable of
conversion into a drug having addiction | 26 | | forming or addiction sustaining
liability.
|
| | | SB2341 Engrossed | - 19 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (ee) "Opium poppy" means the plant of the species Papaver
| 2 | | somniferum L., except its seeds.
| 3 | | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | 4 | | solution or other liquid form of medication intended for | 5 | | administration by mouth, but the term does not include a form | 6 | | of medication intended for buccal, sublingual, or transmucosal | 7 | | administration. | 8 | | (ff) "Parole and Pardon Board" means the Parole and Pardon | 9 | | Board of
the State of Illinois or its successor agency.
| 10 | | (gg) "Person" means any individual, corporation, | 11 | | mail-order pharmacy,
government or governmental subdivision or | 12 | | agency, business trust, estate,
trust, partnership or | 13 | | association, or any other entity.
| 14 | | (hh) "Pharmacist" means any person who holds a license or | 15 | | certificate of
registration as a registered pharmacist, a local | 16 | | registered pharmacist
or a registered assistant pharmacist | 17 | | under the Pharmacy Practice Act.
| 18 | | (ii) "Pharmacy" means any store, ship or other place in | 19 | | which
pharmacy is authorized to be practiced under the Pharmacy | 20 | | Practice Act.
| 21 | | (ii-5) "Pharmacy shopping" means the conduct prohibited | 22 | | under subsection (b) of Section 314.5 of this Act. | 23 | | (ii-10) "Physician" (except when the context otherwise | 24 | | requires) means a person licensed to practice medicine in all | 25 | | of its branches. | 26 | | (jj) "Poppy straw" means all parts, except the seeds, of |
| | | SB2341 Engrossed | - 20 - | LRB100 17957 MRW 33141 b |
|
| 1 | | the opium
poppy, after mowing.
| 2 | | (kk) "Practitioner" means a physician licensed to practice | 3 | | medicine in all
its branches, dentist, optometrist, podiatric | 4 | | physician,
veterinarian, scientific investigator, pharmacist, | 5 | | physician assistant,
advanced practice registered nurse,
| 6 | | licensed practical
nurse, registered nurse, emergency medical | 7 | | services personnel, hospital, laboratory, or pharmacy, or | 8 | | other
person licensed, registered, or otherwise lawfully | 9 | | permitted by the
United States or this State to distribute, | 10 | | dispense, conduct research
with respect to, administer or use | 11 | | in teaching or chemical analysis, a
controlled substance in the | 12 | | course of professional practice or research.
| 13 | | (ll) "Pre-printed prescription" means a written | 14 | | prescription upon which
the designated drug has been indicated | 15 | | prior to the time of issuance; the term does not mean a written | 16 | | prescription that is individually generated by machine or | 17 | | computer in the prescriber's office.
| 18 | | (mm) "Prescriber" means a physician licensed to practice | 19 | | medicine in all
its branches, dentist, optometrist, | 20 | | prescribing psychologist licensed under Section 4.2 of the | 21 | | Clinical Psychologist Licensing Act with prescriptive | 22 | | authority delegated under Section 4.3 of the Clinical | 23 | | Psychologist Licensing Act, podiatric physician, or
| 24 | | veterinarian who issues a prescription, a physician assistant | 25 | | who
issues a
prescription for a controlled substance
in | 26 | | accordance
with Section 303.05, a written delegation, and a |
| | | SB2341 Engrossed | - 21 - | LRB100 17957 MRW 33141 b |
|
| 1 | | written collaborative agreement required under Section 7.5
of | 2 | | the
Physician Assistant Practice Act of 1987, an advanced | 3 | | practice registered
nurse with prescriptive authority | 4 | | delegated under Section 65-40 of the Nurse Practice Act and in | 5 | | accordance with Section 303.05, a written delegation,
and a | 6 | | written
collaborative agreement under Section 65-35 of the | 7 | | Nurse Practice Act, an advanced practice registered nurse | 8 | | certified as a nurse practitioner, nurse midwife, or clinical | 9 | | nurse specialist who has been granted authority to prescribe by | 10 | | a hospital affiliate in accordance with Section 65-45 of the | 11 | | Nurse Practice Act and in accordance with Section 303.05, or an | 12 | | advanced practice registered nurse certified as a nurse | 13 | | practitioner, nurse midwife, or clinical nurse specialist who | 14 | | has full practice authority pursuant to Section 65-43 of the | 15 | | Nurse Practice Act.
| 16 | | (nn) "Prescription" means a written, facsimile, or oral | 17 | | order, or an electronic order that complies with applicable | 18 | | federal requirements,
of
a physician licensed to practice | 19 | | medicine in all its branches,
dentist, podiatric physician or | 20 | | veterinarian for any controlled
substance, of an optometrist in | 21 | | accordance with Section 15.1 of the Illinois Optometric | 22 | | Practice Act of 1987, of a prescribing psychologist licensed | 23 | | under Section 4.2 of the Clinical Psychologist Licensing Act | 24 | | with prescriptive authority delegated under Section 4.3 of the | 25 | | Clinical Psychologist Licensing Act, of a physician assistant | 26 | | for a
controlled substance
in accordance with Section 303.05, a |
| | | SB2341 Engrossed | - 22 - | LRB100 17957 MRW 33141 b |
|
| 1 | | written delegation, and a written collaborative agreement | 2 | | required under
Section 7.5 of the
Physician Assistant Practice | 3 | | Act of 1987, of an advanced practice registered
nurse with | 4 | | prescriptive authority delegated under Section 65-40 of the | 5 | | Nurse Practice Act who issues a prescription for a
controlled | 6 | | substance in accordance
with
Section 303.05, a written | 7 | | delegation, and a written collaborative agreement under | 8 | | Section 65-35 of the Nurse Practice Act, of an advanced | 9 | | practice registered nurse certified as a nurse practitioner, | 10 | | nurse midwife, or clinical nurse specialist who has been | 11 | | granted authority to prescribe by a hospital affiliate in | 12 | | accordance with Section 65-45 of the Nurse Practice Act and in | 13 | | accordance with Section 303.05 when required by law, or of an | 14 | | advanced practice registered nurse certified as a nurse | 15 | | practitioner, nurse midwife, or clinical nurse specialist who | 16 | | has full practice authority pursuant to Section 65-43 of the | 17 | | Nurse Practice Act.
| 18 | | (nn-5) "Prescription Information Library" (PIL) means an | 19 | | electronic library that contains reported controlled substance | 20 | | data. | 21 | | (nn-10) "Prescription Monitoring Program" (PMP) means the | 22 | | entity that collects, tracks, and stores reported data on | 23 | | controlled substances and select drugs pursuant to Section 316. | 24 | | (oo) "Production" or "produce" means manufacture, | 25 | | planting,
cultivating, growing, or harvesting of a controlled | 26 | | substance other than methamphetamine.
|
| | | SB2341 Engrossed | - 23 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (pp) "Registrant" means every person who is required to | 2 | | register
under Section 302 of this Act.
| 3 | | (qq) "Registry number" means the number assigned to each | 4 | | person
authorized to handle controlled substances under the | 5 | | laws of the United
States and of this State.
| 6 | | (qq-5) "Secretary" means, as the context requires, either | 7 | | the Secretary of the Department or the Secretary of the | 8 | | Department of Financial and Professional Regulation, and the | 9 | | Secretary's designated agents. | 10 | | (rr) "State" includes the State of Illinois and any state, | 11 | | district,
commonwealth, territory, insular possession thereof, | 12 | | and any area
subject to the legal authority of the United | 13 | | States of America.
| 14 | | (rr-5) "Stimulant" means any drug that (i) causes an | 15 | | overall excitation of central nervous system functions, (ii) | 16 | | causes impaired consciousness and awareness, and (iii) can be | 17 | | habit-forming or lead to a substance abuse problem, including | 18 | | but not limited to amphetamines and their analogs, | 19 | | methylphenidate and its analogs, cocaine, and phencyclidine | 20 | | and its analogs. | 21 | | (rr-10) "Synthetic drug" includes, but is not limited to, | 22 | | any synthetic cannabinoids or piperazines or any synthetic | 23 | | cathinones as provided for in Schedule I. | 24 | | (ss) "Ultimate user" means a person who lawfully possesses | 25 | | a
controlled substance for his or her own use or for the use of | 26 | | a member of his or her
household or for administering to an |
| | | SB2341 Engrossed | - 24 - | LRB100 17957 MRW 33141 b |
|
| 1 | | animal owned by him or her or by a member
of his or her | 2 | | household.
| 3 | | (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15; | 4 | | 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; | 5 | | 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff. | 6 | | 1-1-18; revised 10-6-17.)
| 7 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | 8 | | Sec. 204. (a) The controlled substances listed in this | 9 | | Section are
included in Schedule I. | 10 | | (b) Unless specifically excepted or unless listed in | 11 | | another
schedule, any of the following opiates, including their | 12 | | isomers,
esters, ethers, salts, and salts of isomers, esters, | 13 | | and ethers,
whenever the existence of such isomers, esters, | 14 | | ethers and salts is
possible within the specific chemical | 15 | | designation: | 16 | | (1) Acetylmethadol; | 17 | | (1.1) Acetyl-alpha-methylfentanyl | 18 | | (N-[1-(1-methyl-2-phenethyl)-
| 19 | | 4-piperidinyl]-N-phenylacetamide); | 20 | | (2) Allylprodine; | 21 | | (3) Alphacetylmethadol, except
| 22 | | levo-alphacetylmethadol (also known as levo-alpha-
| 23 | | acetylmethadol, levomethadyl acetate, or LAAM); | 24 | | (4) Alphameprodine; | 25 | | (5) Alphamethadol; |
| | | SB2341 Engrossed | - 25 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (6) Alpha-methylfentanyl
| 2 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| 3 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| 4 | | propanilido) piperidine; | 5 | | (6.1) Alpha-methylthiofentanyl
| 6 | | (N-[1-methyl-2-(2-thienyl)ethyl-
| 7 | | 4-piperidinyl]-N-phenylpropanamide); | 8 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | 9 | | (7.1) PEPAP
| 10 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | 11 | | (8) Benzethidine; | 12 | | (9) Betacetylmethadol; | 13 | | (9.1) Beta-hydroxyfentanyl
| 14 | | (N-[1-(2-hydroxy-2-phenethyl)-
| 15 | | 4-piperidinyl]-N-phenylpropanamide); | 16 | | (10) Betameprodine; | 17 | | (11) Betamethadol; | 18 | | (12) Betaprodine; | 19 | | (13) Clonitazene; | 20 | | (14) Dextromoramide; | 21 | | (15) Diampromide; | 22 | | (16) Diethylthiambutene; | 23 | | (17) Difenoxin; | 24 | | (18) Dimenoxadol; | 25 | | (19) Dimepheptanol; | 26 | | (20) Dimethylthiambutene; |
| | | SB2341 Engrossed | - 26 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (21) Dioxaphetylbutyrate; | 2 | | (22) Dipipanone; | 3 | | (23) Ethylmethylthiambutene; | 4 | | (24) Etonitazene; | 5 | | (25) Etoxeridine; | 6 | | (26) Furethidine; | 7 | | (27) Hydroxpethidine; | 8 | | (28) Ketobemidone; | 9 | | (29) Levomoramide; | 10 | | (30) Levophenacylmorphan; | 11 | | (31) 3-Methylfentanyl
| 12 | | (N-[3-methyl-1-(2-phenylethyl)-
| 13 | | 4-piperidyl]-N-phenylpropanamide); | 14 | | (31.1) 3-Methylthiofentanyl
| 15 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
| 16 | | 4-piperidinyl]-N-phenylpropanamide); | 17 | | (32) Morpheridine; | 18 | | (33) Noracymethadol; | 19 | | (34) Norlevorphanol; | 20 | | (35) Normethadone; | 21 | | (36) Norpipanone; | 22 | | (36.1) Para-fluorofentanyl
| 23 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 24 | | 4-piperidinyl]propanamide); | 25 | | (37) Phenadoxone; | 26 | | (38) Phenampromide; |
| | | SB2341 Engrossed | - 27 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (39) Phenomorphan; | 2 | | (40) Phenoperidine; | 3 | | (41) Piritramide; | 4 | | (42) Proheptazine; | 5 | | (43) Properidine; | 6 | | (44) Propiram; | 7 | | (45) Racemoramide; | 8 | | (45.1) Thiofentanyl
| 9 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
| 10 | | 4-piperidinyl]-propanamide); | 11 | | (46) Tilidine; | 12 | | (47) Trimeperidine; | 13 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
| 14 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| 15 | | N-phenylpropanamide); | 16 | | (49) Furanyl fentanyl (FU-F); | 17 | | (50) Butyryl fentanyl; | 18 | | (51) Valeryl fentanyl; | 19 | | (52) Acetyl fentanyl; | 20 | | (53) Beta-hydroxy-thiofentanyl; | 21 | | (54) 3,4-dichloro-N-[2-
| 22 | | (dimethylamino)cyclohexyl]-N-
| 23 | | methylbenzamide (U-47700); | 24 | | (55) 4-chloro-N-[1-[2-
| 25 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
| 26 | | benzenesulfonamide (W-18); |
| | | SB2341 Engrossed | - 28 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (56) 4-chloro-N-[1-(2-phenylethyl)
| 2 | | -2-piperidinylidene]-benzenesulfonamide (W-15); | 3 | | (57) acrylfentanyl (acryloylfentanyl). | 4 | | (c) Unless specifically excepted or unless listed in | 5 | | another
schedule, any of the following opium derivatives, its | 6 | | salts, isomers
and salts of isomers, whenever the existence of | 7 | | such salts, isomers and
salts of isomers is possible within the | 8 | | specific chemical designation: | 9 | | (1) Acetorphine; | 10 | | (2) Acetyldihydrocodeine; | 11 | | (3) Benzylmorphine; | 12 | | (4) Codeine methylbromide; | 13 | | (5) Codeine-N-Oxide; | 14 | | (6) Cyprenorphine; | 15 | | (7) Desomorphine; | 16 | | (8) Diacetyldihydromorphine (Dihydroheroin); | 17 | | (9) Dihydromorphine; | 18 | | (10) Drotebanol; | 19 | | (11) Etorphine (except hydrochloride salt); | 20 | | (12) Heroin; | 21 | | (13) Hydromorphinol; | 22 | | (14) Methyldesorphine; | 23 | | (15) Methyldihydromorphine; | 24 | | (16) Morphine methylbromide; | 25 | | (17) Morphine methylsulfonate; | 26 | | (18) Morphine-N-Oxide; |
| | | SB2341 Engrossed | - 29 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (19) Myrophine; | 2 | | (20) Nicocodeine; | 3 | | (21) Nicomorphine; | 4 | | (22) Normorphine; | 5 | | (23) Pholcodine; | 6 | | (24) Thebacon. | 7 | | (d) Unless specifically excepted or unless listed in | 8 | | another
schedule, any material, compound, mixture, or | 9 | | preparation which contains
any quantity of the following | 10 | | hallucinogenic substances, or which
contains any of its salts, | 11 | | isomers and salts of isomers, whenever the
existence of such | 12 | | salts, isomers, and salts of isomers is possible
within the | 13 | | specific chemical designation (for the purposes of this
| 14 | | paragraph only, the term "isomer" includes the optical, | 15 | | position and
geometric isomers): | 16 | | (1) 3,4-methylenedioxyamphetamine
| 17 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
| 18 | | methylenedioxyamphetamine, MDA); | 19 | | (1.1) Alpha-ethyltryptamine
| 20 | | (some trade or other names: etryptamine;
| 21 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 22 | | 3-(2-aminobutyl)indole; a-ET; and AET); | 23 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); | 24 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| 25 | | (also known as: N-ethyl-alpha-methyl-
| 26 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
| | | SB2341 Engrossed | - 30 - | LRB100 17957 MRW 33141 b |
|
| 1 | | and MDEA); | 2 | | (2.2) N-Benzylpiperazine (BZP); | 3 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); | 4 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | 5 | | (4) 3,4,5-trimethoxyamphetamine (TMA); | 6 | | (5) (Blank); | 7 | | (6) Diethyltryptamine (DET); | 8 | | (7) Dimethyltryptamine (DMT); | 9 | | (7.1) 5-Methoxy-diallyltryptamine; | 10 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | 11 | | (9) Ibogaine (some trade and other names:
| 12 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 13 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| 14 | | indole; Tabernanthe iboga); | 15 | | (10) Lysergic acid diethylamide; | 16 | | (10.1) Salvinorin A; | 17 | | (10.5) Salvia divinorum (meaning all parts of the plant | 18 | | presently classified
botanically as Salvia divinorum, | 19 | | whether growing or not, the
seeds thereof, any extract from | 20 | | any part of that plant, and every compound,
manufacture, | 21 | | salts, isomers, and salts of
isomers whenever the existence | 22 | | of such salts, isomers, and salts of
isomers is possible | 23 | | within the specific chemical designation, derivative, | 24 | | mixture, or preparation of that plant, its
seeds or | 25 | | extracts);
| 26 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
| | | SB2341 Engrossed | - 31 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (12) Peyote (meaning all parts of the plant presently | 2 | | classified
botanically as Lophophora williamsii
Lemaire, | 3 | | whether growing or not, the
seeds thereof, any extract from | 4 | | any part of that plant, and every compound,
manufacture, | 5 | | salts, derivative, mixture, or preparation of that plant, | 6 | | its
seeds or extracts); | 7 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); | 8 | | (14) N-methyl-3-piperidyl benzilate; | 9 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| 10 | | (also known as N-hydroxy-alpha-methyl-
| 11 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); | 12 | | (15) Parahexyl; some trade or other names:
| 13 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| 14 | | dibenzo (b,d) pyran; Synhexyl; | 15 | | (16) Psilocybin; | 16 | | (17) Psilocyn; | 17 | | (18) Alpha-methyltryptamine (AMT); | 18 | | (19) 2,5-dimethoxyamphetamine
| 19 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 20 | | (20) 4-bromo-2,5-dimethoxyamphetamine
| 21 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 22 | | 4-bromo-2,5-DMA); | 23 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| 24 | | Some trade or other names: 2-(4-bromo-
| 25 | | 2,5-dimethoxyphenyl)-1-aminoethane;
| 26 | | alpha-desmethyl DOB, 2CB, Nexus; |
| | | SB2341 Engrossed | - 32 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (21) 4-methoxyamphetamine
| 2 | | (4-methoxy-alpha-methylphenethylamine;
| 3 | | paramethoxyamphetamine; PMA); | 4 | | (22) (Blank); | 5 | | (23) Ethylamine analog of phencyclidine.
| 6 | | Some trade or other names:
| 7 | | N-ethyl-1-phenylcyclohexylamine,
| 8 | | (1-phenylcyclohexyl) ethylamine,
| 9 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | 10 | | (24) Pyrrolidine analog of phencyclidine. Some trade | 11 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | 12 | | PHP; | 13 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | 14 | | (26) 2,5-dimethoxy-4-ethylamphetamine
| 15 | | (another name: DOET); | 16 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| 17 | | (another name: TCPy); | 18 | | (28) (Blank); | 19 | | (29) Thiophene analog of phencyclidine (some trade
| 20 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 21 | | 2-thienyl analog of phencyclidine; TPCP; TCP); | 22 | | (29.1) Benzothiophene analog of phencyclidine . Some | 23 | | trade or other names: BTCP or benocyclidine; | 24 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); | 25 | | (30) Bufotenine (some trade or other names:
| 26 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
| | | SB2341 Engrossed | - 33 - | LRB100 17957 MRW 33141 b |
|
| 1 | | 3-(2-dimethylaminoethyl)-5-indolol;
| 2 | | 5-hydroxy-N,N-dimethyltryptamine;
| 3 | | N,N-dimethylserotonin; mappine); | 4 | | (31) (Blank); | 5 | | (32) (Blank); | 6 | | (33) (Blank); | 7 | | (34) (Blank); | 8 | | (34.5) (Blank); | 9 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | 10 | | (2-methyloctan-2-yl)-6a,7, | 11 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol | 12 | | Some trade or other names: HU-210; | 13 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- | 14 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | 15 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, | 16 | | salts, and salts of isomers; Some trade or other | 17 | | names: HU-210, Dexanabinol; | 18 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 19 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 20 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | 21 | | Some trade or other names: HU-211; | 22 | | (37) (Blank); | 23 | | (38) (Blank); | 24 | | (39) (Blank); | 25 | | (40) (Blank); | 26 | | (41) (Blank); |
| | | SB2341 Engrossed | - 34 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (42) Any compound structurally derived from | 2 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane | 3 | | by substitution at the nitrogen atom of the indole ring by | 4 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 5 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 6 | | 1-(N-methyl-2-piperidinyl)methyl, or | 7 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 8 | | in the indole ring to any extent, whether or not | 9 | | substituted in the naphthyl ring to any extent. Examples of | 10 | | this structural class include, but are not limited to, | 11 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; | 12 | | (43) Any compound structurally derived from | 13 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | 14 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | 15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | in the pyrrole ring to any extent, whether or not | 19 | | substituted in the naphthyl ring to any extent. Examples of | 20 | | this structural class include, but are not limited to, | 21 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; | 22 | | (44) Any compound structurally derived from | 23 | | 1-(1-naphthylmethyl)indene by substitution at the | 24 | | 3-position of the indene ring by alkyl, haloalkyl, alkenyl, | 25 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 26 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
| | | SB2341 Engrossed | - 35 - | LRB100 17957 MRW 33141 b |
|
| 1 | | 2-(4-morpholinyl)ethyl whether or not further substituted | 2 | | in the indene ring to any extent, whether or not | 3 | | substituted in the naphthyl ring to any extent. Examples of | 4 | | this structural class include, but are not limited to, | 5 | | JWH-176; | 6 | | (45) Any compound structurally derived from | 7 | | 3-phenylacetylindole by substitution at the nitrogen atom | 8 | | of the indole ring with alkyl, haloalkyl, alkenyl, | 9 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 10 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 11 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 12 | | in the indole ring to any extent, whether or not | 13 | | substituted in the phenyl ring to any extent. Examples of | 14 | | this structural class include, but are not limited to, | 15 | | JWH-167, JWH-250, JWH-251, and RCS-8; | 16 | | (46) Any compound structurally derived from | 17 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the | 18 | | 5-position of the phenolic ring by alkyl, haloalkyl, | 19 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 20 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the | 22 | | cyclohexyl ring to any extent. Examples of this structural | 23 | | class include, but are not limited to, CP 47, 497 and its | 24 | | C8 homologue (cannabicyclohexanol); | 25 | | (46.1) Any compound structurally derived from | 26 | | 3-(benzoyl) indole with substitution at the nitrogen atom |
| | | SB2341 Engrossed | - 36 - | LRB100 17957 MRW 33141 b |
|
| 1 | | of the indole ring by an alkyl, haloalkyl, alkenyl, | 2 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 3 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 4 | | 2-(4-morpholinyl)ethyl group whether or not further | 5 | | substituted in the indole ring to any extent and whether or | 6 | | not substituted in the phenyl ring to any extent. Examples | 7 | | of this structural class include, but are not limited to, | 8 | | AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and | 9 | | RCS-4; | 10 | | (47) (Blank); | 11 | | (48) (Blank); | 12 | | (49) (Blank); | 13 | | (50) (Blank); | 14 | | (51) (Blank); | 15 | | (52) (Blank); | 16 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine . | 17 | | Some trade or other names: 2C-T-7; | 18 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine . Some trade | 19 | | or other names: 2C-E; | 20 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine . Some | 21 | | trade or other names: 2C-D; | 22 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine . Some | 23 | | trade or other names: 2C-C; | 24 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine . Some trade | 25 | | or other names: 2C-I; | 26 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine . Some |
| | | SB2341 Engrossed | - 37 - | LRB100 17957 MRW 33141 b |
|
| 1 | | trade or other names: 2C-T-2; | 2 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine . | 3 | | Some trade or other names: 2C-T-4; | 4 | | (53.7) 2,5-dimethoxyphenethylamine . Some trade or | 5 | | other names: 2C-H; | 6 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine . Some trade | 7 | | or other names: 2C-N; | 8 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine . Some | 9 | | trade or other names: 2C-P; | 10 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine . Some | 11 | | trade or other names: 2C-G; | 12 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C | 13 | | phenethylamine referred to in subparagraphs (20.1), (53), | 14 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), | 15 | | (53.8), (53.9), and (53.10) including, but not limited to, | 16 | | 25I-NBOMe and 25C-NBOMe; | 17 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; | 18 | | (55) (Blank); | 19 | | (56) (Blank); | 20 | | (57) (Blank); | 21 | | (58) (Blank); | 22 | | (59) 3-cyclopropoylindole with substitution at the | 23 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 24 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 25 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | SB2341 Engrossed | - 38 - | LRB100 17957 MRW 33141 b |
|
| 1 | | on the indole ring to any extent, whether or not | 2 | | substituted on the cyclopropyl ring to any extent: | 3 | | including, but not limited to, XLR11, UR144, FUB-144; | 4 | | (60) 3-adamantoylindole with substitution at the | 5 | | nitrogen atom of the indole ring by alkyl, haloalkyl, | 6 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 7 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 8 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 9 | | on the indole ring to any extent, whether or not | 10 | | substituted on the adamantyl ring to any extent: including, | 11 | | but not limited to, AB-001; | 12 | | (61) N-(adamantyl)-indole-3-carboxamide with | 13 | | substitution at the nitrogen atom of the indole ring by | 14 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 15 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 16 | | 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indole ring to any extent, whether or not | 19 | | substituted on the adamantyl ring to any extent: including, | 20 | | but not limited to, APICA/2NE-1, STS-135; | 21 | | (62) N-(adamantyl)-indazole-3-carboxamide with | 22 | | substitution at a nitrogen atom of the indazole ring by | 23 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 24 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 25 | | 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | SB2341 Engrossed | - 39 - | LRB100 17957 MRW 33141 b |
|
| 1 | | on the indazole ring to any extent, whether or not | 2 | | substituted on the adamantyl ring to any extent: including, | 3 | | but not limited to, AKB48, 5F-AKB48; | 4 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester | 5 | | with substitution at the nitrogen atom of the indole ring | 6 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, | 7 | | cycloalkylethyl, aryl halide, alkyl aryl halide, | 8 | | 1-(N-methyl-2-piperidinyl)methyl, or | 9 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 10 | | on the indole ring to any extent, whether or not | 11 | | substituted on the quinoline ring to any extent: including, | 12 | | but not limited to, PB22, 5F-PB22, FUB-PB-22; | 13 | | (64) 3-(1-naphthoyl)indazole with substitution at the | 14 | | nitrogen atom of the indazole ring by alkyl, haloalkyl, | 15 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, | 16 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indazole ring to any extent, whether or not | 19 | | substituted on the naphthyl ring to any extent: including, | 20 | | but not limited to, THJ-018, THJ-2201; | 21 | | (65) 2-(1-naphthoyl)benzimidazole with substitution at | 22 | | the nitrogen atom of the benzimidazole ring by alkyl, | 23 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 24 | | aryl halide, alkyl aryl halide, | 25 | | 1-(N-methyl-2-piperidinyl)methyl, or | 26 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
| | | SB2341 Engrossed | - 40 - | LRB100 17957 MRW 33141 b |
|
| 1 | | on the benzimidazole ring to any extent, whether or not | 2 | | substituted on the naphthyl ring to any extent: including, | 3 | | but not limited to, FUBIMINA; | 4 | | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- | 5 | | 3-carboxamide with substitution on the nitrogen atom of the | 6 | | indazole ring by alkyl, haloalkyl, alkenyl, | 7 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 8 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 9 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 10 | | on the indazole ring to any extent: including, but not | 11 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; | 12 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 13 | | indazole-3-carboxamide with substitution on the nitrogen | 14 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, | 15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 18 | | on the indazole ring to any extent: including, but not | 19 | | limited to, ADB-PINACA, ADB-FUBINACA; | 20 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- | 21 | | indole-3-carboxamide with substitution on the nitrogen | 22 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, | 23 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 24 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 25 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 26 | | on the indole ring to any extent: including, but not |
| | | SB2341 Engrossed | - 41 - | LRB100 17957 MRW 33141 b |
|
| 1 | | limited to, ADBICA, 5F-ADBICA; | 2 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- | 3 | | 3-carboxamide with substitution on the nitrogen atom of the | 4 | | indole ring by alkyl, haloalkyl, alkenyl, | 5 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 6 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 7 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 8 | | on the indole ring to any extent: including, but not | 9 | | limited to, ABICA, 5F-ABICA; | 10 | | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- | 11 | | methylbutanoate with substitution on the nitrogen atom of | 12 | | the indazole ring by alkyl, haloalkyl, alkenyl, | 13 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl | 14 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 15 | | 2-(4-morpholinyl)ethyl, whether or not further substituted | 16 | | on the indazole ring to any extent: including, but not | 17 | | limited to, AMB, 5F-AMB ; . | 18 | | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- | 19 | | dimethylbutanoate with substitution on the nitrogen
atom | 20 | | of the indazole ring by alkyl, haloalkyl, alkenyl,
| 21 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl | 22 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 23 | | 2-(4-morpholinyl)ethyl, whether or not further substituted
| 24 | | on the indazole ring to any extent: including, but not
| 25 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; | 26 | | (72) Methyl 2-(1H-indole-3-carboxamido)-3- |
| | | SB2341 Engrossed | - 42 - | LRB100 17957 MRW 33141 b |
|
| 1 | | methylbutanoate with substitution on the nitrogen atom
of | 2 | | the indole ring by alkyl, haloalkyl, alkenyl,
| 3 | | cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl | 4 | | halide, 1-(N-methyl-2-piperidinyl)methyl,
or | 5 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 6 | | on the indazole ring to any extent:
including, but not | 7 | | limited to, MMB018, MMB2201,
and AMB-CHMICA; | 8 | | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- | 9 | | dimethylbutanoate with substitution
on the nitrogen atom | 10 | | of the indole ring by alkyl,
haloalkyl, alkenyl, | 11 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 12 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 13 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 14 | | on the
indazole ring to any extent: including, but
not | 15 | | limited to, MDMB-CHMICA; | 16 | | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- | 17 | | indazole-3-carboxamide with
substitution on the nitrogen | 18 | | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, | 19 | | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl | 20 | | halide,
1-(N-methyl-2-piperidinyl)methyl, or | 21 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted | 22 | | on the indazole ring to any
extent: including, but not | 23 | | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; | 24 | | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- | 25 | | 3-carboxamide with substitution on
the nitrogen atom of the | 26 | | indole ring by alkyl,
haloalkyl, alkenyl, |
| | | SB2341 Engrossed | - 43 - | LRB100 17957 MRW 33141 b |
|
| 1 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl | 2 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or | 3 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted | 4 | | on the indazole
ring to any extent: including, but not | 5 | | limited to,
APP-PICA and 5-fluoro-APP-PICA; | 6 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name | 7 | | 4-AcO-DMT; | 8 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade | 9 | | name 5-MeO-MIPT; | 10 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); | 11 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); | 12 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); | 13 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
| 14 | | (4-HO-MiPT); | 15 | | (82) Fluorophenylpiperazine; | 16 | | (83) Methoxetamine; | 17 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- | 18 | | ethcathinone). | 19 | | (e) Unless specifically excepted or unless listed in | 20 | | another
schedule, any material, compound, mixture, or | 21 | | preparation which contains
any quantity of the following | 22 | | substances having a depressant effect on
the central nervous | 23 | | system, including its salts, isomers, and salts of
isomers | 24 | | whenever the existence of such salts, isomers, and salts of
| 25 | | isomers is possible within the specific chemical designation: | 26 | | (1) mecloqualone; |
| | | SB2341 Engrossed | - 44 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (2) methaqualone; and | 2 | | (3) gamma hydroxybutyric acid. | 3 | | (f) Unless specifically excepted or unless listed in | 4 | | another schedule,
any material, compound, mixture, or | 5 | | preparation which contains any quantity
of the following | 6 | | substances having a stimulant effect on the central nervous
| 7 | | system, including its salts, isomers, and salts of isomers: | 8 | | (1) Fenethylline; | 9 | | (2) N-ethylamphetamine; | 10 | | (3) Aminorex (some other names:
| 11 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 12 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| 13 | | salts, optical isomers, and salts of optical isomers; | 14 | | (4) Methcathinone (some other names:
| 15 | | 2-methylamino-1-phenylpropan-1-one;
| 16 | | Ephedrone; 2-(methylamino)-propiophenone;
| 17 | | alpha-(methylamino)propiophenone; N-methylcathinone;
| 18 | | methycathinone; Monomethylpropion; UR 1431) and its
| 19 | | salts, optical isomers, and salts of optical isomers; | 20 | | (5) Cathinone (some trade or other names:
| 21 | | 2-aminopropiophenone; alpha-aminopropiophenone;
| 22 | | 2-amino-1-phenyl-propanone; norephedrone); | 23 | | (6) N,N-dimethylamphetamine (also known as:
| 24 | | N,N-alpha-trimethyl-benzeneethanamine;
| 25 | | N,N-alpha-trimethylphenethylamine); | 26 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
| | | SB2341 Engrossed | - 45 - | LRB100 17957 MRW 33141 b |
|
| 1 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | 2 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); | 3 | | (9) Halogenated amphetamines and
| 4 | | methamphetamines - any compound derived from either
| 5 | | amphetamine or methamphetamine through the substitution
| 6 | | of a halogen on the phenyl ring, including, but not
| 7 | | limited to, 2-fluoroamphetamine, 3-
| 8 | | fluoroamphetamine and 4-fluoroamphetamine; | 9 | | (10) Aminopropylbenzofuran (APB):
| 10 | | including 4-(2-Aminopropyl) benzofuran, 5-
| 11 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
| 12 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; | 13 | | (11) Aminopropyldihydrobenzofuran (APDB):
| 14 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
| 15 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
| 16 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
| 17 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; | 18 | | (12) Methylaminopropylbenzofuran
| 19 | | (MAPB): including 4-(2-methylaminopropyl)
| 20 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
| 21 | | 6-(2-methylaminopropyl)benzofuran
| 22 | | and 7-(2-methylaminopropyl)benzofuran. | 23 | | (g) Temporary listing of substances subject to emergency | 24 | | scheduling.
Any material, compound, mixture, or preparation | 25 | | that contains any quantity
of the following substances: | 26 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
| | | SB2341 Engrossed | - 46 - | LRB100 17957 MRW 33141 b |
|
| 1 | | (benzylfentanyl), its optical isomers, isomers, salts,
and | 2 | | salts of isomers; | 3 | | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- | 4 | | phenylpropanamide (thenylfentanyl),
its optical isomers, | 5 | | salts, and salts of isomers. | 6 | | (h) Synthetic cathinones. Unless specifically excepted, | 7 | | any chemical compound which is not approved by the United | 8 | | States Food and Drug Administration or, if approved, is not | 9 | | dispensed or possessed in accordance with State or federal law, | 10 | | not including bupropion, structurally derived from | 11 | | 2-aminopropan-1-one by substitution at the 1-position with | 12 | | either phenyl, naphthyl, or thiophene ring systems, whether or | 13 | | not the compound is further modified in one or more of the | 14 | | following ways: | 15 | | (1) by substitution in the ring system to any extent | 16 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or | 17 | | halide substituents, whether or not further substituted in | 18 | | the ring system by one or more other univalent | 19 | | substituents. Examples of this class include, but are not | 20 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); | 21 | | (2) by substitution at the 3-position with an acyclic | 22 | | alkyl substituent. Examples of this class include, but are | 23 | | not limited to, 2-methylamino-1-phenylbutan-1-one | 24 | | (buphedrone); or | 25 | | (3) by substitution at the 2-amino nitrogen atom with | 26 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by |
| | | SB2341 Engrossed | - 47 - | LRB100 17957 MRW 33141 b |
|
| 1 | | inclusion of the 2-amino nitrogen atom in a cyclic | 2 | | structure. Examples of this class include, but are not | 3 | | limited to, Dimethylcathinone, Ethcathinone, and | 4 | | a-Pyrrolidinopropiophenone (a-PPP) ; or . | 5 | | Any other synthetic cathinone which is not approved by the | 6 | | United States Food and Drug Administration or, if approved, is | 7 | | not dispensed or possessed in accordance with State or federal | 8 | | law. | 9 | | (i) Synthetic cannabinoids or piperazines. Any synthetic | 10 | | cannabinoid or piperazine which is not approved by the United | 11 | | States Food and Drug Administration or, if approved, which is | 12 | | not dispensed or possessed in accordance with State and federal | 13 | | law. | 14 | | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; | 15 | | 100-368, eff. 1-1-18; revised 10-5-17.)
|
|